AstraZeneca PLC (AZN) – Benefitting from broad-based, diverse source of revenue

AstraZeneca PLC (AZN) (Q2FY23)

Introduction

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.

It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases.

Highlights

In 1HFY23, the company’s revenue distribution reflects a strategic focus on a broad-based and diverse source of income within the field of healthcare. The oncology sector contributes the largest portion, accounting for 39% of total revenue, followed by Cardiovascular, Renal, and Metabolism (CVRM) at 24%, and Rare Disease at 17%.

Stock performance

AstraZeneca’s stock price showed a volatile trend in past 3-months period. It declined by 7.16% during the period. The stock price increased by 3.52% in past 1-year. The stock has a 52-week high of $76.56 and its 52-week low is $52.65.

In the past 3 years, the stock has given returns of 23.44%. AZN has a 50-day moving Avg. and 200-day moving Avg. of $69.52 and $69.41, respectively.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 33

To download the previous quarter’s equity report CLICK HERE

To Download other equity/ stock reports CLICK HERE

Follow our LinkedIn page for more updates.